中紅醫療(300981.SZ):聘任陳俊為公司總經理
格隆匯1月7日丨中紅醫療(300981.SZ)公佈,公司於2022年1月7日召開第三屆董事會第六次會議,審議通過了《關於聘任公司總經理的議案》,同意聘任陳俊為公司總經理,任期自第三屆董事會第六次會議通過之日起至第三屆董事會任期屆滿之日止。
公吿顯示,陳俊,男,1980年6月出生,中國國籍,無境外永久居住權。2002年本科畢業於武漢理工大學,2013年考取西安交通大學材料工程碩士研究生。2002年2月至2008年4月任武漢智訊創源科技發展股份有限公司技術部主管,2008年4月至2017年3月曆任北京伏爾特技術有限公司技術總監、營銷副總兼子公司總經理,2017年3月至2020年5月任四川科倫藥業股份有限公司器械事業部副總經理兼生產公司總經理,2020年8月至2021年12月任上海復星醫藥(集團)股份有限公司上海創新科技總經理兼器械板塊總裁助理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.